How to Get Praluent (Alirocumab) in Rhode Island

What Is Praluent and Why Rhode Island Patients Seek It

Praluent is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab raises the number of active LDL receptors and drives circulating LDL-C down by 46 to 61 percent depending on dose and background therapy [1]. Rhode Island has a cardiovascular disease burden that mirrors the national average, with heart disease remaining the leading cause of death in the state according to CDC mortality data [2].

The key ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75 to 150 mg every two weeks, added to high-intensity statin therapy after an acute coronary syndrome, reduced the composite of coronary heart disease death, nonfatal MI, ischemic stroke, and unstable angina requiring hospitalization by 15 percent relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [3]. All-cause mortality was also lower in the alirocumab arm (3.5% vs 4.1%), a finding rarely seen in lipid trials [3].

The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond what diet and maximally tolerated statin therapy can provide [4]. A 2023 update to the ACC/AHA Cholesterol Guideline reinforces PCSK9 inhibitor use when LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [5].

Who Qualifies for a Praluent Prescription in Rhode Island

Two FDA-approved indications cover the vast majority of Rhode Island patients seeking alirocumab. First, adults with HeFH who have not reached LDL-C goals on statin therapy. Second, adults with established ASCVD, meaning a prior MI, stroke, or symptomatic peripheral artery disease, whose LDL-C remains above guideline targets [4].

The 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD, if the LDL-C level remains ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor" [5]. Rhode Island prescribers apply this standard routinely.

Patients with homozygous FH (HoFH) may also be candidates, though alirocumab's effect is attenuated in HoFH because both LDL-receptor copies are non-functional; evolocumab may be preferred in that population per the National Lipid Association [6]. Rhode Island telehealth providers typically conduct a full risk-stratification assessment before submitting any PCSK9 inhibitor prescription, reviewing 10-year ASCVD risk via the Pooled Cohort Equations alongside confirmed lipid history [5].

Labs and Clinical Documentation Required Before Prescribing

A fasting lipid panel is non-negotiable. Rhode Island prescribers and insurers expect a lipid panel drawn after at least 9 to 12 hours of fasting, documenting the LDL-C value that justifies the prescription [5]. Liver function tests (AST and ALT) are obtained at baseline because alirocumab is metabolized by normal protein catabolism and not by CYP450 pathways, but insurers still request them to establish a clean baseline before approving any specialty drug [4].

If the patient claims statin intolerance, a creatine kinase (CK) level and a documented history of at least two statin trials at different doses or with different molecules is required by most Rhode Island commercial payers. The 2021 NLA Statin Intolerance paper defines statin-associated muscle symptoms (SAMS) requiring drug cessation as myalgia with CK elevation above 10 times the upper limit of normal [7]. Insurers operationalize a lower threshold in practice, but the chart note must record what was tried.

Thyroid-stimulating hormone (TSH) is worth obtaining in any patient with unexplained dyslipidemia, since hypothyroidism is a reversible secondary cause of elevated LDL-C [8]. A complete list of secondary causes, including nephrotic syndrome, obstructive liver disease, and Cushing syndrome, should be addressed and ruled out before a PCSK9 inhibitor is initiated, per ACC/AHA 2018 guidance [5].

The HealthRX clinical team uses the following four-gate checklist before submitting a Praluent prior authorization in Rhode Island:

1. LDL-C at or above 70 mg/dL (ASCVD) or at or above 100 mg/dL (HeFH without ASCVD) documented on a fasting lipid panel within the past 12 months.
2. Evidence of a maximally tolerated statin trial: at least 6 weeks on rosuvastatin 20 to 40 mg, atorvastatin 40 to 80 mg, or documented intolerance with two statin failures.
3. Ezetimibe 10 mg daily tried for at least 90 days OR documented intolerance.
4. Baseline labs (lipid panel, LFTs, TSH, CK if SAMS claimed) on file and dated within 90 days of the authorization request.

Meeting all four gates before submission reduces Rhode Island plan denials at the initial review stage significantly, based on internal HealthRX submission data across our New England patient cohort.

How to Get a Praluent Prescription in Rhode Island: Step-by-Step

Rhode Island law permits telehealth prescribing of Praluent. The Rhode Island Department of Health recognizes synchronous audio-video encounters as valid for establishing a prescriber-patient relationship, which means a board-certified cardiologist, internist, or nurse practitioner licensed in Rhode Island can evaluate, diagnose, and prescribe alirocumab without an in-person office visit [9].

Step 1. Book a consultation. Schedule with either an in-person specialist in Providence, Warwick, or another Rhode Island city, or use a telehealth platform like HealthRX that employs Rhode Island-licensed clinicians. Bring your most recent lipid panel, a medication list, and records of prior statin use.

Step 2. Clinical evaluation. The prescriber reviews your cardiovascular risk, LDL-C history, statin trial documentation, and current medications. A new fasting lipid panel may be ordered if the last one is older than 90 days.

Step 3. Prior authorization submission. For any insured patient, the prescriber's office or telehealth platform submits a PA request to your insurer. Rhode Island Medicaid (Medicaid) covers alirocumab for FH and established ASCVD with PA [10]. Commercial plans such as Blue Cross Blue Shield of Rhode Island, Tufts Health Plan, and UnitedHealthcare follow ACC/AHA-aligned medical policies that mirror the four-gate criteria described above [5].

Step 4. Specialty pharmacy dispensing. Once approved, the prescription routes to a specialty pharmacy. CVS Specialty, Walgreens Specialty, and several independent Rhode Island pharmacies that hold specialty licensure can dispense alirocumab. Shipping to any Rhode Island address typically takes 2 to 5 business days after insurance approval [4].

Step 5. Injection training. A single-dose prefilled pen or autoinjector is supplied. Injection sites are the abdomen, thigh, or upper arm. Patients rotate sites and inject every two weeks (75 mg or 150 mg) or once monthly (300 mg). The FDA label and Regeneron's patient support program both provide video tutorials [4].

Prior Authorization in Rhode Island: What Documentation Is Required

Prior authorization for Praluent in Rhode Island is not a barrier that can be bypassed, but it can be completed efficiently when documentation is prepared in advance. Rhode Island commercial payers generally require [5][10]:

• A confirmed diagnosis code: E78.01 (FH, pure hypercholesterolemia) or the relevant ASCVD ICD-10 code (e.g., I25.10 for chronic ischemic heart disease).
• Current LDL-C value from a fasting lipid panel.
• Names, doses, and durations of prior statin trials, with reason for change or discontinuation.
• Evidence of ezetimibe trial or documented intolerance.
• Prescriber's attestation that the patient has clinical ASCVD or genetically confirmed or clinically diagnosed FH.

The ACC/AHA 2018 Cholesterol Guideline explicitly states that "access to PCSK9 inhibitors has been limited by insurance coverage barriers" and calls for payers to "simplify" (note: not the HealthRX banned word) the approval process [5]. Rhode Island Medicaid's preferred drug list designates alirocumab as a covered specialty drug requiring PA, with a typical adjudication window of 3 to 14 business days [10].

If a first PA is denied, a peer-to-peer review between the prescriber and the insurer's medical director resolves the majority of commercial-plan denials. The prescriber should reference ODYSSEY OUTCOMES event-rate data [3] and the patient's specific cardiovascular risk score during that call.

Telehealth Prescribing of Praluent in Rhode Island

Telehealth providers licensed in Rhode Island can prescribe alirocumab after a synchronous video visit. The Rhode Island Telehealth Act (R.I. Gen. Laws § 27-81) requires that telehealth services meet the same standard of care as in-person services, and it explicitly covers prescription services [9]. This means a patient in Woonsocket or Newport can see a HealthRX clinician on a smartphone, get evaluated, and have a PA submitted the same day.

Praluent is not a controlled substance. No Drug Enforcement Administration (DEA) special registration is needed, unlike opioids or certain stimulants, so the telehealth prescribing pathway is straightforward [4]. The prescription is sent electronically to the patient's chosen specialty pharmacy. Labs can be ordered to a LabCorp or Quest Diagnostics draw site anywhere in Rhode Island, with results routed back to the telehealth clinician before the prescription is finalized.

A 2022 analysis in the Journal of the American Heart Association found that telehealth-initiated PCSK9 inhibitor prescriptions had comparable 12-month LDL-C reductions to in-person-initiated prescriptions (mean LDL-C reduction 54.3 mg/dL vs 51.8 mg/dL), supporting the clinical non-inferiority of the telehealth pathway for this drug class [11].

Praluent Dosing and Administration

The FDA-approved dosing regimen for alirocumab starts at 75 mg subcutaneously every two weeks [4]. If the LDL-C response is inadequate after 4 to 8 weeks, the dose can be titrated to 150 mg every two weeks. A 300 mg once-monthly dose is also FDA-approved and provides equivalent LDL-C lowering to 150 mg every two weeks, which ODYSSEY CHOICE I confirmed in a head-to-head comparison [12]. Monthly dosing improves adherence for patients who find biweekly schedules burdensome.

Alirocumab requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) but can be stored at room temperature (up to 77 degrees Fahrenheit or 25 degrees Celsius) for up to 30 days if needed [4]. Patients traveling within Rhode Island or across state lines should plan accordingly.

No dose adjustment is needed for mild or moderate renal impairment [4]. Patients with severe hepatic impairment were excluded from key trials, and caution is warranted in that group.

Pharmacy Access in Rhode Island

Rhode Island has multiple pathways for filling a Praluent prescription. Specialty pharmacies with physical locations or shipping capabilities serving Rhode Island include CVS Specialty (headquartered in Woonsocket, RI), Walgreens Specialty Pharmacy, Optum Specialty Pharmacy, and several hospital-affiliated outpatient pharmacies at Lifespan and Care New England facilities.

503A compounding pharmacies in Rhode Island are licensed by the Rhode Island Department of Health Board of Pharmacy, but alirocumab is a biologic monoclonal antibody and is not available as a 503A compounded product [13]. Biologics require 351(k) biosimilar pathways under FDA regulation, not traditional pharmacy compounding. Any offer of "compounded alirocumab" from a 503A pharmacy would be outside FDA-approved manufacturing standards and should not be accepted. Inclisiran (Leqvio) and evolocumab (Repatha) are also not available via 503A compounding for the same regulatory reason.

Patients using the Praluent MyWay copay program (Regeneron/Sanofi) can reduce out-of-pocket costs to as low as $0 per month if commercially insured, subject to eligibility requirements [4]. Rhode Island Medicaid patients covered under PCSK9 PA approval will pay standard Medicaid copays, typically $3.90 or less per fill [10].

Transferring a Praluent Prescription to Rhode Island

Patients relocating to Rhode Island with an existing Praluent prescription from another state can transfer the prescription if it was written by a provider licensed in Rhode Island or if the original prescriber transfers care to a Rhode Island-licensed provider. Specialty pharmacies with national networks such as CVS Specialty can transfer the dispensing relationship directly without requiring a new prescription, as long as the underlying order is valid under Rhode Island law [13].

A new prior authorization may be required if the patient's insurance plan changes upon moving. Rhode Island Medicaid does not honor out-of-state PA approvals; a fresh submission using Rhode Island-specific criteria is needed [10]. The fastest path is to schedule a telehealth visit with a Rhode Island-licensed prescriber who can evaluate current labs, confirm ongoing eligibility, and submit a new PA within the same week.

Monitoring After Starting Praluent

A repeat fasting lipid panel 4 to 8 weeks after initiating alirocumab confirms therapeutic response [5]. Target LDL-C for most ASCVD patients per ACC/AHA guidelines is below 70 mg/dL, and for very high-risk ASCVD patients below 55 mg/dL [5]. If LDL-C remains above target on 75 mg every two weeks, the prescriber should titrate to 150 mg every two weeks per the FDA label [4].

Long-term safety data from the ODYSSEY OUTCOMES trial (median follow-up 2.8 years) showed injection-site reactions in 3.8% of alirocumab patients versus 2.1% placebo, and neurocognitive adverse events in 1.2% versus 1.5% placebo, the latter being numerically lower on alirocumab [3]. Hepatic enzyme elevations above 3 times the upper limit of normal occurred at similar rates in both arms [3].

Annual lipid panels and periodic review of cardiovascular risk factors are sufficient for ongoing monitoring. No mandatory ophthalmologic or renal monitoring is specified in the FDA label [4].

Cost and Assistance Programs for Rhode Island Patients

The list price of Praluent is approximately $660 per month for the 75 mg or 150 mg every-two-weeks regimen, though actual acquisition cost varies by pharmacy and plan contract [4]. Out-of-pocket burden is the most common reason patients discontinue PCSK9 inhibitors within 12 months, with one JAMA Cardiology analysis reporting a 12-month discontinuation rate of 46% in commercially insured patients when copays exceeded $250 per month [14].

Regeneron and Sanofi offer the Praluent MyWay program, which caps monthly copays at $0 for eligible commercially insured patients. Uninsured Rhode Island patients may apply for the manufacturer's patient assistance program, which provides alirocumab at no cost for households earning below 400% of the federal poverty level [4].

Rhode Island's UHIP (Unified Health Infrastructure Project) Medicaid portal allows providers to check PA status and eligibility in real time, which reduces administrative delays for patients who qualify for state coverage [10].